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Abstract
Autosomal dominant polycystic kidney disease (ADPKD) constitutes the fourth cause of end-stage renal disease in 
Europe. The course of the disease varies widely among patients with ADPKD. Due to the emergence of new possibili-
ties of pharmacotherapy, it has become crucial to identify the group of patients with the fastest rate and risk of disease 
progression. This particular group of patients will benefit most from the therapy and they are the best candidates 
for clinical trials. At the early stages of ADPKD typical markers of severity and progression of the disease remain 
unchanged in contrast to the kidney volume, which increases continuously in an exponential way. Therefore, the use  
of height-adjusted total kidney volume as a biomarker should become a mandatory diagnostic option. Also, quanti-
tative MRI techniques are promising biomarkers for the evaluation of disease severity and could provide additional 
insights into its course.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) 
is a well-recognised clinical entity, with a multisystemic 
phenotype, originating from mutation of polycystin-1 and 
polycystin-2 encoding genes PKD1 and PKD2 [1]. The dis-
ease is believed to be encountered in 1 : 400 to 1 : 1,000 
live births [1]. The main clinical presentation of this highly 
prevalent genetic disorder is the cystic remodelling of the 
kidneys, leading to progressive deterioration in their func-
tion and development of chronic kidney disease (CKD). 
CKD occurs late in the course of the disease, in typical cas-
es in the fourth to fifth decade of life [1].
Slowing the CKD progression remains the principal 
clinical concern nowadays. Besides the benefit at the in-
dividual level, success in this respect could have an enor-
mous economic impact, as ADPKD constitutes the fourth 
cause of end-stage renal disease (ESRD) and accounts for 
5% to 10% of cases treated with renal replacement therapy 
(RRT) in Europe alone [2].
The course of the disease, whose diagnosis is typically 
made much earlier than its complications occur, allowed 
the implementation of numerous clinical trials intended 
to slow the progression of this detrimental disease. How-
ever, it was found that a significant limitation impacting 
the recruitment and the performance of those trials is the 
variability of the disease progression.
The European Medicines Agency (EMEA) in 2017 
and Food and Drug Administration (FDA) in April 2018 
approved the first specific drug for slowing down the pro-
gression of ADPKD – tolvaptan, a vasopressin V2 recep-
tor antagonist [3]. Therefore, accurate monitoring of the 
disease at its early stages has become even more impor-
tant than ever before. It is crucial to identify the group 
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of patients with the fastest rate and risk of progression. 
This particular group will benefit most from the pharma-
cotherapy.
Diagnosis
The diagnosis of ADPKD is based on positive family histo-
ry, radiological imaging, and DNA tests in selected cases. 
The family history is an important step in the diagnostic 
process. Nevertheless, demographic changes make this pa-
rameter less reliable. Also, in up to 10% of cases, a patho-
genic variant of the polycystin encoding genes may occur 
de novo [4]. Genetic testing is not a useful screening tool 
because it can identify only approximately 70% of the hun-
dreds of different PKD1 and PKD2 mutations [5].
That explains the significant role of radiologic imaging 
techniques, among which conventional ultrasound is used 
most frequently for its high diagnostic accuracy, accessi-
bility, and cost-effectiveness.
Ultrasound diagnosis of patients with a known muta-
tion in the PKD1 gene is based on age-dependent Ravine’s 
criteria (Table 1) [6].
It is well established that mutation in the PKD2 (about 
15% of cases) gene is usually associated with a less severe 
form of the disease. Therefore, Revine’s criteria cannot be 
used in these patients (particularly below the age of 30), 
mainly because of the higher risk of false negative results, 
which reduces the sensitivity of the test [7].
The majority of patients seen in clinical practice have un-
known genotype status. Pei et al. proposed unified diagnos-
tic criteria that can be used regardless of the mutation type 
(PKD1/PKD2/Unknown) in patients older than 15 years 
old, with a positive family history of the disease [7]. Cur-
rently, these criteria are mainly used in screening (Table 2).
Computed tomography is not routinely used in the 
diagnosis of ADPKD mainly due to the use of ionizing 
radiation.
Magnetic resonance imaging is expensive and time- 
consuming, but due to its excellent spatial resolution, 
the Working Group PTN recommends the use of non- 
enhanced magnetic resonance imaging (MRI) sequences 
in some clinical scenarios [8]. For those subjects who re-
quire disease exclusion with high certainty (for example 
living donors with a positive family history), MRI is rec-
ommended for both obtaining a definite diagnosis and 
disease exclusion. Specifically, among subjects who are 
at risk of ADPKD ages 15-40 years old, the presence of 
a total of > 10 renal cysts can be considered as sufficient 
for diagnosis, while the presence of < 5 cysts precludes 
the diagnosis [7]. MRI can also be used for a diagnostic 
purpose in patients with a negative family history of the 
disease.
Monitoring disease progression
ADPKD is a disease that progresses over the decades until 
kidney failure finally occurs by the fifth to seventh decade 
of life in the majority of patients [1]. Serum creatinine lev-
el and estimated glomerular filtration rate (eGFR) do not 
change until the fourth or fifth decade of life in contrast 
to the kidney volume, which grows continuously, expo-
nentially. Therefore assessment of the disease progression 
requires determination of the size of kidneys.
According to the Consortium for Radiologic Imag-
ing Studies of Polycystic Kidney Disease (CRISP), MRI 
derived height-adjusted total kidney volume (ht-TKV) is 
the best radiological biomarker to assess the severity and 
risk of progression of renal insufficiency in patients with 
typical variant of ADPKD [5,9]. 
In rare, atypical variants of renal cystic remodeling 
(e.g. unilateral cysts distribution) measurement of ht-TKV 
is not recommended (Table 3).
Ultrasonography is the basic diagnostic tool, but it 
does not allow accurate TKV measurements, underesti-
mating them by 25% [10]. Computed tomography (CT) 
is just as accurate as MR assessment; however, it cannot be 
used due to the risk of ionising radiation in a long-term 
follow-up.
Irazabal et al. proposed to associate the ht-TKV with 
the age of patients [11]. This allowed assignment of the 
class 1 study participants into one of the five subclasses 
(1A-1E) characterised by the increasing rate of ht-TKV 
accretion in time. This classification allows us to predict 
the course of the disease and thus define the subgroup 
Table 1. Ravine’s criteria [6]
Number of cysts
Age (years) Positive family history Negative family history
< 30 ≥ 2 in one or both kidneys ≥ 5
30-59 ≥ 2 in each kidney ≥ 5
≥ 60 ≥ 4 in each kidney ≥ 8
Table 2. Unified ultrasound diagnostic criteria [7]
Confirmation Exclusion
Age 
(years)
Number of cysts Age 
(years)
Number of cysts
15-39 ≥ 3 uni- or bi-lateral 15-39 Not diagnostic
40-59 ≥ 2 in each kidney ≥ 40 < 2 in each kidney
≥ 60 ≥ 4 in each kidney
Table 3. Radiologic phenotypes of polycystic kidneys classified as atypical 
variants, type 2 [11]
Atypical
Focal disease Parenchymal atrophy
Unilateral Unilateral
Asymmetric Bilateral
Segmental
Lop-sided
 MRI imaging in ADPKD patients
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of patients most at risk of rapid progression to ESRD. 
The estimated frequency of ESRD at ten years increased 
from A to E (2.4%, 11.0%, 37.8%, 47.1%, and 66.9%, re-
spectively). The classification is easily available on the 
Mayo Clinic Rochester, Minnesota, USA website [12]. 
There exists a wide range of urinary tract complica-
tions in ADPKD including infections, intracystic bleed-
ing, lithiasis and cyst rupture resulting in retroperitoneal 
haemorrhage. A crucial task of imaging diagnostics is to 
differentiate these conditions and enable doctors to apply 
appropriate causal treatment accurately.
Complex cysts represent haemorrhage, infection, or 
malignancy. Hemorrhagic cysts are hyperechoic on the 
US, hyperdense on CT imaging, and hyperintense on the 
T1 MRI sequence. It can be challenging to determine if 
a complex cyst contains blood or proteinaceous fluid even 
in a non-enhanced MRI examination. Both entities are 
hyperintense on the T1 sequence and hypointense on the 
T2 sequence or bright on both series. They do not show 
enhancement after gadolinium administration and disap-
pear on the subtracted images [13].
Infected cysts show an increase of intensity on DWI, 
fluid-fluid levels or wall thickening. Also gas within the 
cyst is an indicator of infection [14].
Another challenge is how to distinguish between fo-
cal lesions and a complex cyst. The Bosniak CT-based 
scale can be helpful, but the intravenous administration 
of a potentially nephrotoxic iodine contrast medium is 
usually contraindicated. MRI findings related to RCC 
are a heterogeneous mass of low-to-intermediate signal 
on T1-weighted images that increases in signal intensity 
on T2-weighted images and intense enhancement after 
injection of gadolinium. However, we have to remember 
the risk of nephrogenic systemic fibrosis associated with 
the use of gadolinium.
Total kidney volume measurements
Gold standard: manual tracing/stereology method (sTKV)
The gold standard method to assess TKV is the manual 
tracing method. Kidney volumes should be measured on 
the coronal fat, saturated T2-sequence images. Kidney 
boundaries are manually traced using the commercial-
ly available software. Kidney volume is calculated from 
the set of contiguous images by summing the products 
of the area measurements within the kidney multiplied 
by the slice thickness (Figure 1). Nonrenal parenchy-
ma (renal hilus) should be excluded from the analysis. 
Assessment of sTKV is time-consuming and needs spe-
cific software, which limits its applicability for clinical 
care [15].
Estimated ellipsoid method (eTKV)
In clinical practice, the ellipsoid method is mainly used. 
eTKV correlates strongly with sTKV, without systematic 
underestimation and overestimation. The average time 
needed to measure sTKV was 45 minutes, compared with 
7 minutes for eTKV [11]. For each kidney, the length is 
measured as the average maximal longitudinal diameter 
measured in the coronal and sagittal plane (fat-saturat-
ed T2-sequence). Width is obtained from the transver-
sal image at maximum transversal diameter, and depth 
is measured from the same image perpendicular to the 
width measurement (Figures 2-4). The eTKV ellipsoid is 
calculated as the sum of the left eTKV and right KV, both 
derived by the equation [15]:
2 × Width × Depth
eTKV = .
π
6 × (Lengthcoronal + Lengthsagittal)
Figure 1. T2 fat saturated image with a VOI of kidney Figure 2. T2 BLADE image with width and depth marks
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Estimated midslice method (mTKV)
To estimate mTKV mid slice (half the sum of numbers of 
the first and last slice that contains the kidney) of the coro-
nal fat saturated T2-sequence should be selected separate-
ly for each kidney. mTKV is calculated as the sum of the 
mTKV of the right and left kidney from the equation [15]:
mTKVleft kidney = 0.624 × number of slices covering  
the kidney × slice thickness
mTKVright kidney = 0.637 × number of slices covering  
the kidney × slice thickness
Semiautomated/automated method (sa/aTKV): shape  
or boundary automatic/semiautomated detection, 
usage of specific software is necessary
To sum up: mainly the ellipsoid method is used in clinical 
practice because it is fast and accurate compared to man-
ual tracking TKV, and no specific software is necessary.
Recommendations of the Working Group  
and ADPKD guidelines
Several national and international initiatives released 
recommendations and guidelines on ADPKD imaging 
approaches and diagnosis. Among the most recent (Feb-
ruary 2019) are recommendations of the Working Group 
of PTN [8]. They are summarized in Table 4.
Quantitative MRI sequences
Quantitative MRI sequences are new, promising biomark-
ers. They could provide a more accurate and earlier assess-
ment of renal diseases and enable quicker interventions to 
stop or slow down function decline.
Therefore, quantitative techniques that can add to the 
assessment of renal structure are needed.
According to the study “Quantitative MRI of kidneys 
in renal disease” quantitative techniques have shown rel-
evant structural and functional changes in the ADPKD 
kidneys compared to healthy controls [14]. The following 
quantitative MR imaging sequences were found to be sig-
nificant:
– blood-oxygen-level-dependent imaging (BOLD),
– diffusion-weighted imaging (DWI),
– magnetic resonance elastography (MRE),
– magnetisation transfer imaging (MTR).
In the study mentioned above, in the group of patients 
with an early stage of ADPKD, the researchers found a re-
duction in the BOLD parameter (R2*) which suggests 
tissue alteration possibly resulting from decreased vascu-
lar density or changes in tissue viability. With DWI they 
Figure 3. T2 HASTE image with length of kidney in the coronal plane Figure 4. T2 HASTE image with length kidney in the sagittal plane
Table 4. Recommendations for ADPKD imaging approaches in Poland
MRI T2-sequence is a method of choice for measuring TKV.
TKV, preferably with MRI, should be a part of the initial assessment in ADPKD patients. However, it is not recommended to monitor the progression  
of the disease by this method.
Mayo classification can be used to assess disease risk of progression.
The MRI description needs to be standardised. It should include the measurement of the maximum length, width, thickness of the kidney and the 
estimated TKV.
Due to the lack of availability of repeated MRI TKV measurements in Poland, doctors may use the ultrasound assessment and assume that patients 
aged < 46 years with currently correct kidney function and TKV > 650 ml or renal length > 16.5 cm are at risk for developing renal failure.
 MRI imaging in ADPKD patients
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found a reduction in the pseudo-diffusion component 
as well as a reduction in the derived perfusion fraction, 
which is evidence for changes in vascular structure and 
function. With MRE they found a reduction in tissue stiff-
ness.
Diagnostic information can also be elicited from the 
image texture. Although there is no strict definition of 
the image texture, it is easily perceived by human eyes. 
Image texture refers to the appearance, structure, and 
arrangement of different intensity levels within an image 
[16]. Voxels in the image are perceived to exhibit specific 
brightness, colour, roughness, directionality, randomness, 
smoothness, grain, uniformity, and density. In the medical 
sense, texture describes the micro- and macro-structure 
and three-dimensional shape of the selected organ [16]. 
To obtain information about tissue properties precisely 
defined parameters (texture features) are needed. For ex-
ample, the texture feature entropy measures the degree of 
disorder within the kidney. Thus kidneys with seemingly 
random cyst distributions will have a higher entropy value 
[17]. According to the study “Image texture features pre-
dict a decrease in renal function in patients with autosomal 
dominant polycystic kidney disease” texture characteristics 
may explain differences in the rate of progression in differ-
ent phenotypes of kidneys [17]. Individual texture features 
were found to predict subsequent renal function decline. 
These features characterised factors such as the degree of 
disorder within the kidney, differences in cyst size and 
number, and whether the kidneys were composed of many 
similar-appearing regions to differentiate the patients [17].
Diffusion tensor imaging (DTI) gives us much infor-
mation about water motion along axes fitted to a sym-
metric matrix, named diffusion tensor, resulting in a 3D 
model. Fractional anisotropy (FA) is a value scaled from 
0 (no preferred diffusion direction calculated) to 1 (strong 
directionality of the tensor in one direction), which meas-
ures the diffusion anisotropy. By use of a tensor, it is pos-
sible to calculate a 3D model, which represents the diffu-
sion directions with lines called tracts [18]. According to 
the study “3 Tesla-diffusion tensor imaging in autosomal 
dominant polycystic kidney disease: the nephrologist’s 
point of view” parenchymal FA was significantly lower, 
and ADC was higher among ADPKD patients. 3T-DTI 
seems to be a promising tool that could be used to eval-
uate ADPKD patients, detecting early structure changes 
[19]. It is likely that the combination of texture feature 
analysis with current biomarkers will improve personal-
ised clinical decision making in ADPKD.
Arterial spin labelling (ASL) is an MRI method for 
measuring perfusion using the patient’s water molecules 
as tracers. ASL offers the opportunity to characterise renal 
perfusion and could inform on changes in vascular geom-
etry and restrictions in regional kidney blood flow [20].
These new MR quantitative techniques should be fur-
ther explored.
Conclusions
At the early stages of ADPKD typical markers of severi-
ty and progression of the disease remain unchanged, in 
contrast to the TKV, which increases continuously in an 
exponential way. Therefore, the use of MRI ht-TKV as 
a biomarker should become a more accessible diagnos-
tic option. Disease course varies widely among patients 
with ADPKD, so it is crucial to identify the group of pa-
tients with the fastest rate and risk of progression. This 
particular group of patients will benefit most from phar-
macotherapy and they are the best candidates for clinical 
trials. Also, quantitative MRI techniques are promising 
biomarkers for ADPKD evaluation and could provide 
additional insights into the course of the disease. More 
extensive studies are still needed to evaluate quantitative 
MRI techniques further to assess their usefulness in clin-
ical decision making.
Slowing down the progression of the disease is not 
only crucial for the patient as an individual but is also 
strongly economically justified. However, this could not 
be attained without a reliable imaging approach.
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